当前位置: X-MOL 学术Ther. Adv. Med. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma.
Therapeutic Advances in Medical Oncology ( IF 4.3 ) Pub Date : 2019-07-25 , DOI: 10.1177/1758835919864850
Zhimin Tong 1 , Alicia Mejia 1 , Omkara Veeranki 1 , Anuj Verma 2 , Arlene M Correa 3 , Rashmi Dokey 1 , Viren Patel 1 , Luisa Maren Solis 2 , Barbara Mino 2 , Riham Kathkuda 2 , Jaime Rodriguez-Canales 2 , Steven H Lin 4 , Sunil Krishnan 4 , Scott Kopetz 5 , Mariela Blum 5 , Jaffer A Ajani 5 , Wayne L Hofstetter 3 , Dipen M Maru 6
Affiliation  

Preoperative chemotherapy or chemoradiation followed by surgery have improved survival outcomes and the likelihood of margin-negative esophagogastrectomy in patients with locoregional esophageal adenocarcinoma (EAC).1 However, these patients’ 5-year survival rates remain low.2,3 Biomarker-driven targeted therapies have had limited success in EAC patients, primarily in less than 20% of those with stage IV human epidermal growth factor receptor 2 (Her2-neu)-overexpressing disease who receive trastuzumab.4–6 To date, no targeted agent has demonstrated benefit as an adjunct to 5-fluorouracil-based chemotherapy or chemoradiation in patients with locally advanced EAC.

中文翻译:

通过一种新的 CDK9/p-TEFb 抑制剂靶向 CDK9 和 MCL-1,联合或不联合 5-氟尿嘧啶治疗食管腺癌。

术前化疗或放化疗后手术改善了局部区域食管腺癌 (EAC) 患者的生存结果和切缘阴性食管胃切除术的可能性。1然而,这些患者的 5 年生存率仍然很低。2,3生物标志物驱动的靶向治疗在 EAC 患者中取得的成功有限,主要是在接受曲妥珠单抗治疗的 IV 期人类表皮生长因子受体 2 (Her2-neu) 过度表达疾病患者中不到 20%。4-6迄今为止,尚无靶向药物作为 5-氟尿嘧啶为基础的化疗或放化疗的辅助手段对局部晚期 EAC 患者有益。
更新日期:2019-07-25
down
wechat
bug